Novan up as FDA to decide on nod for skin infection treatment by Jan '24

NVN Liquidation

07/03/2023 14:00

** Shares of drug developer Novan Inc  NOVN.O  rise 5.3% to $1.39 premarket 
    ** Co says U.S. FDA has accepted its marketing application of experimental
treatment, berdazimer gel, for molluscum contagiosum
    ** FDA to decide on marketing approval for the treatment by Jan. 5, 2024 -
Novan 
    ** Molluscum contagiosum is a type of viral skin infection that causes spots
on the skin 
    ** Novan shares have gained ~12% in the past three months 

 (Reporting by Raghav Mahobe)
 ((Raghav.Mahobe@thomsonreuters.com;))